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Objective: To evaluate the protective effect of different doses of inhaled fenoterol (F) on bronchoconstriction induced by methacholine
(M). Design: randomized double-blind study. Setting: Referrence center. Participants: 9 children (aged from 7 to 15 years old),
with mild or moderate asthma and allergic to D. pteronyssinus. Intervention: On the first day, the M concentration necessary to
induce a 20% fall in the forced expiratory volume in the first second (FEV1; PC20FEV1) was determined using closed circuit inhalation(De Vilbiss 646). On subsequent days, the children inhaled a dose of F (25 or 50 or 100 or 200 mg) through the same circuit and,
after 15 minutes the FEV1 was measured, becoming the basal value. Bronchoprovocation was then initiated using the concentration
prior to the PC20FEV1 of the first day and continuing until there was a 20% fall in the FEV1. This concentration was the “new”
PC20FEV1. Results: F in a dose of 25 mg protected 2 of the 9 children, in a dose of 50 mg protected 4 of the 9 and in doses of 100
and 200 mg protected all children. We did not observe any relationship between the magnitude of the bronchodilation and
bronchoprotection induced by the inhalation of F. Conclusions: Our results suggest that a dose of 100 mg of F is capable of
inducing bronchoprotection in children with mild/moderate asthma.
Uniterms: Asthma. Children. Bronchial hyperreactivity. Beta agonists. Fenoterol. Methacholine.
INTRODUCTION
nhaled short-acting beta 2 agonists constitute the
first choice medication for the treatment of acute
asthma flares and in preventing bronchospasms
induced by exercise.1-5 One of the most widely used in
Brazil is fenoterol in solution form for nebulization. It is
I
also available as a metered dose inhaler (MDI) in doses of
100 and 200 mg /puff. Previous studies have tried to relate
its use to the increase in asthma mortality, which we did
not observe in a previous study6 and was not confirmed
by a meta-analysis study.7
Previous studies have shown that fenoterol is capable
of blocking the bronchospasm induced by the inhalation
of histamine8-12 and methacholine8,9 and also protect against
exercise-induced asthma (EIA).13 A 50 mg dose was
enough to avoid EIA13 and 10 mg avoided brocho-
constriction caused by inhaled histamine.12
In this study we evaluate the capacity of inhaled
fenoterol for the protection of methacholine-induced
bronchospasm in Brazilian atopic asthmatic children.
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METHODS
Nine children, from 7 to 15 years of age (6 boys),
with mild or moderate atopic asthma,1 took part in this
study. The atopic status was characterized by a positive
skin prick test to Dermatophagoides pteronyssinus. All
the children were able to perform espirometric
measurements in an appropriate manner.14 This study was
approved by the UNIFESP-EPM Ethical Committee and
the children were enrolled after their parents gave informed
consent.
The patients were submitted to bronchoprovocation
(BPT) with methacholine according to the method
standardized in our Division by Mallozi et al.,15 and
modified from Chai et al.16 Upon being included in the
study, the exclusion intervals of the following drugs were
observed: short-acting beta 2 agonists and aminophylline,
8 hours; ipratropium bromide, 12 hours; slow-releasing
theophylline, 24 hours; classic antihistamines, 7 days; non-
classic antihistamines, 15 days; disodium chromoglycate,
15 days; oral and inhaled corticosteroids, 30 days.
Five BPT’s were carried out, always in the morning,
interspersed with a day of rest. All patients were
asymptomatic and FEV1 was greater than or equal to 80%
of the predicted normal values.17
At the first BPT the methacholine PC20FEV1
(concentration of methacholine capable of inducing a
20% fall in the FEV1 baseline value) was established.
For this BPT, the methacholine was inhaled in
increasing concentrations (0.025; 0.25; 1.0; 2.5; 10.0
and 25.0 mg/mL) until a fall in the FEV1 took place,
greater or equal to 20% of the baseline value. The
methacholine PC20FEV1 calculation was extrapolated
using monolog graph paper.
On subsequent days the patients inhaled fenoterol
15 minutes before the BPT was carried out. The fenoterol
was administered using the same inhalation closed circuit
(De Vilbiss 646) and 02 (5L/min) in different
concentrations each day, distributed using the randomized
double-blind method (25 mg, 50 mg, 100 mg and 200 mg).
The BPT’s were started after the child had inhaled
saline solution to obtain the baseline FEV1. Fenoterol was
then inhaled and 15 minutes later, another FEV1 was
obtained which became the basal value for the remainder
of the test. The BPT began with the inhalation of the
previous concentration of methacholine necessary to obtain
the initial PC20FEV1, followed by larger doses until the
20% fall in the FEV1 was obtained, establishing a new
methacholine PC20FEV1 for each dose of inhaled fenoterol.
The PC20FEV1 with values in excess of 38.78 mg/mL were
considered to be equal to 40.0 mg/mL.
The methacholine PC20FEV1 were expressed in
mg/mL for each inhaled fenoterol concentration and in
relation to the value obtained during the first provocation,
by simple division. To analyse the results, non-parametric
tests were used (Friedman, Fisher) considering the null
hypothesis rejection level at 5%.
RESULTS
All the children underwent the BPT without
presenting any adverse effects. The initial PC20FEV1 of
all of them was equal to or less than 8 mg/mL. The analysis
of the various PC20FEV1 observations showed values
significantly higher than baseline after inhalation of 100
and 200 mg of fenoterol (Table 1).
Table 1
 PC20FEV1 methacholine values after inhalation of different doses of fenoterol.
Child Baseline 25 mg 50 mg 100 mg 200 mg
(a) (b) (c) (d) (e)
1 3.27 3.55 19.50 7.30 7.30
2 0.10 0.008 0.09 0.36 0.35
3 0.0215 0.68 0.63 1.55 5.70
4 3.77 3.77 4.45 16.00 18.40
5 6.75 14.45 15.45 36.50 > 38.78
6 5.90 5.60 9.20 > 38.78 > 38.78
7 8.00 10.00 15.00 > 38.78 > 38.78
8 0.36 0.13 1.275 3.20 5.00
9 1.85 0.42 1.30 6.00 6.40
Mean 3.36 4.29 7.43 16.77 18.13
Friedman: H calculated = 27.727* *p < 0.05
Dunn: a,b < d,e
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The ratio between the two PC20FEV1 values, obtained
before and after protection using the four inhaled doses is
shown in Table 2. Considering a ratio of at least 2 (doubling
dose) as a positive value, the mean ratio after inhalation
of 25 mg of fenoterol was 4.3. However, only 2 patients
were in fact protected. The same result was observed with
the 50 mg dose; in this case 4 of the 9 patients were
protected (p= 0.3147). With the 100 and 200 mg
concentrations all the patients were protected.
The response to the inhalation of different doses of
fenoterol showed, after 15 minutes, a similar increase (9
to 12%) in the FEV1 values, with no significant differences.
DISCUSSION
Short-acting beta 2 agonists, because of their
bronchodilating effect, are widely used in treating acute
exacerbations of asthma and in the prevention of EIA.
The continuous use of these agents has been associated
with a deterioration in the control of asthma and with
mortality.18,19 The main causes for these possible effects have
not been clarified yet and are still unknown, but have been
related to inhaled drugs, especially via metered dose inhaler.20
Worsening of asthma was not proved in recent
studies.21,22 These studies showed that the regular use of
inhaled short-acting beta 2 agonists cause neither harmful
nor beneficial effects in the control of asthmatic patients.
Thus, the recommendation is that these drugs be used only
when necessary, although when an individual patient has
better control of the asthma with continuous use, this
treatment should not be discarded.21
Several asthma management guidelines1-5
recommend the use of beta 2 agonists only as needed (for
acute episodes). Larger doses than recommended for
inhaled beta 2 agonists are not necessary for obtaining the
same bronchodilation: the occasional side effects are dose-
related.1-5
Our study shows that there may be a protective
bronchodilating effect using much smaller doses of
fenoterol, such as 25 and 50 mg, but which do not protect
all patients. This fact was observed with a minimum
protective dose of 100 mg which, for individual patients,
can be evaluated using 25 and 50 mg doses.
Although we evaluated the protective dose of
fenoterol needed to protect against methacholine-induced
bronchospasm, it seems reasonable to recommend the dose
of 100 mg of fenoterol as the initial dose for treatment of
an acute attack of asthma.
Table 2
Ratio between the PC20FEV1 methacholine before and after  inhalation of different doses of fenoterol.
Child 25 mg 50 mg 100 mg 200 mg
(b) (c) (d) (e)
1 1.08 5.96 2.23 2.23
2 0.08 0.90 3.60 3.50
3 31.60 29.30 72.00 265.10
4 1.00 1.18 4.20 4.88
5 2.14 2.29 5.40 5.90
6 0.95 1.60 6.78 6.80
7 1.23 1.90 5.00 5.00
8 0.36 3.54 8.90 13.89
9 0.22 0.70 3.24 3.46
Mean 4.30 5.26 12.37 34.53
Friedman: H calculated = 21.068* *p < 0.05
Dunn: b < d, e c > e
REFERENCES
1. Sociedade Brasileira de Alergia e Imunopatologia,
Sociedade Brasileira de Pediatria, Sociedade Brasileira de
Pneumologia e Tisiologia. 1o Consenso Brasileiro no Manejo
da Asma, São Paulo: Bg Cultural;1994:42.
2. Global Strategy for asthma management and prevention.
NHLBI/WHO Workshop. National Heart, Lung and Blood
Institute publication 1995;95:3659.
3. Spector SL, Nicklas RA. Practice parameters for the
diagnosis and treatment of asthma. J Allergy Clin Immunol
1995;96:707-870.
4. Canadian Thoracic Society, Canadian Paediatric Society,
Canadian Society of Allergy and Immunology, Canadian
Gomez ID, Silva MD, Bueno MP, Solé D, Naspitz CK. Protective effects of different doses of
inhaled fenoterol on methacholine-induced bronchoconstriction in asthmatic children.
 Rev Paul Med 1998;116(6):1834-7
1837
Association of Emergency Physicians, College of Family
Physicians of Canada, and Family Physician Asthma Group of
Canada. Report on the working groups for the Canadian Asthma
Consensus Conference. Can Respir J 1996;3:1B- 44B.
5. National Institutes of Health and National Heart, Lung and
Blood Institute. Practical Guide for the Diagnosis and
Management of Asthma, NIH publication 1997;97:4053.
6. Naspitz CK, Solé D, Salto-Jr JJ. Beta 2 agonists and death
from asthma. J Allergy Clin Immunol 1994;93:677.
7. Mullen M, Mullen B, Carey M. The association between
b-agonist use and death from asthma. A meta-analytic
integration of case-control studies. JAMA 1993;270:1842-5.
8. Bandouvakis J, Cartier A, Roberts R. The effect of
ipratropium bromide and fenoterol on methacholine- and
histamine-induced bronchoconstriction. Br J Dis Chest
1981;75:295-305.
9. Salome CM, Schoeffel RE, Woolcock AJ. Effect of aerosol
and oral fenoterol on histamine and methacholine challenge
in asthmatic subjects. Thorax 1981;36:580-4.
10. Salome CM, Schoeffel RE, Yan K, Woolcock AJ. Effect of
aerosol fenoterol on the severity of bronchial hyperreactivity
in patients with asthma. Thorax 1983;38:854-8.
11. Salome CM, Wright W, Sedgwick CJ, Woolcock AJ. Acute
effects of fenoterol (Berotec) and ipratropium bromide
(Atrovent) alone and in combination on bronchial
hyperresponsiveness in asthmatic subjects In: Black J,
Armour C, editors. Mechanisms in Asthma Pharmacology,
Physiology, and Management. New York: Alan R Liss
1988;405-19.
12. Magnussen H, Rabe KF. Low dose fenoterol aerosol protects
against histamine-induced bronchoconstriction in mild
asthmatics: a dose response study. Clin Exper Allergy
1992;22:690-3.
13. Rabe KF, Jörres R, Magnussen H. The effect of 10, 50 and
200 mg inhaled fenoterol on exercise induced asthma. Clin
Exper Allergy 1993;23:440-5.
14. American Thoracic Society. Lung function testing selection
of reference values and interpretative strategies. Am Rev
Respir Dis 1991;144:1202-18.
15. Mallozi MC, Solé D, Naspitz CK . Broncoprovocação com
histamina e metacolina em crianças com asma brônquica e
crianças normais. J Pneumol 1991;17:69-73.
16. Chai H, Fan RS, Froehlich LA. Standardization of bronchial
inhalation challenge procedures. J Allergy Clin Immunol
1975;56:323-7.
17. Polgar G, Promadaht V. Pulmonary function testing in
children. Philadelphia: WB Saunders 1971;273.
18. Spitzer WO, Suissa S, Ernst P, et al. The use of b-agonists
and the risk of death and near death from asthma. N Engl J
Med 1992;326:501-6.
19. Sears MR, Taylor DR, Print CG. Regular inhaled b-agonist
treatment in bronchial asthma. Lancet 1990;336:1391-6.
20. Piacentini GL, Peroni DG, Vicentini L, et al. Beta 2
agonists, exposure to allergens and bronchial
hyperreactivity in childen with allergic asthma. Pediatr
Med Chir 1995;17:515-7.
21. Drazen JF, Israel E, Boushey HA, et al. Comparison of
regularly scheduled with as needed use of albuterol in mild
asthma. N Engl J Med 1996;335:841-7.
22. Apter AJ, Reisine ST, Willard A, et al. The effect of inhaled
albuterol in moderate to severe asthma. J Allergy Clin
Immunol 1996;98:295-301.
RESUMO
Objetivos: Avaliar o efeito protetor de diferentes doses de fenoterol (F) inalado sobre a broncoconstrição induzida por metacolina
(M). Tipo de Estudo: estudo duplo-cego e randomizado. Local: Centro de referência. Participantes: Nove crianças (7 a 15
anos) com asma leve ou moderada, alérgicas ao D. pteronyssinus. Intervenção: As doses de F (25 ou 50 ou 100 ou 200 mg)
foram administradas por inalação com circuito fechado (De Vilbiss 646). No primeiro dia determinou-se a concentração de M
capaz de induzir queda de 20% nos valores de VEF1 (CP20VEF1). Nos dias subseqüentes, inalavam a dose de F pelo mesmo
circuito medindo o VEF1 15 minutos após (referência). A seguir iniciavam a broncoprovocação pela concentração anterior à da
CP20VEF1 do primeiro dia e prosseguiam até que houvesse queda de 20% no valor do VEF1 para a determinação do novo
CP20VEF1. Resultados: O F inalado na dose de 25 mg protegeu 2/9 crianças e na de 50 mg houve proteção de 4/9 crianças.
Todos os pacientes foram protegidos com as doses de 100 e 200 mg. Não observamos relação entre a magnitude da
broncodilatação e broncoproteção induzidas pela inalação do F. Conclusões: Nossos resultados sugerem que a dose de 100
mg de F é protetora da broncoconstrição em crianças com asma leve/moderada.
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